Patents Examined by Savitha Rao
  • Compositions and methods of use of phorbal esters for the treatment of stroke
    Patent number: 9550722
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 24, 2017
    Assignee: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators
    Patent number: 9550746
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: January 24, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Class- and isoform-specific HDAC inhibitors and uses thereof
    Patent number: 9540317
    Abstract: The present invention is drawn to compounds of Formula (I) below: and the pharmaceutically acceptable salts thereof, wherein R and R? are defined herein. The compounds are useful inhibitors of histone deacetylases (HDAC).
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: January 10, 2017
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Ralph Mazitschek, James E. Bradner
  • Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
    Patent number: 9532987
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: January 3, 2017
    Assignee: Genentech, Inc.
    Inventors: Marcia Belvin, John Moffat, Mark Merchant
  • Targeting the steroidogenic pathway for treating and/or preventing allergic diseases
    Patent number: 9534221
    Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: January 3, 2017
    Assignee: National Jewish Health
    Inventors: Erwin W. Gelfand, Meiqin Wang, Yi Jia
  • Compositions and methods of use of phorbol esters for the treatment of stroke
    Patent number: 9533938
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 3, 2017
    Assignee: Biosuccess Biotech Co., Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Non-digestible sugar-coated products and process
    Patent number: 9526743
    Abstract: A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the stomach and small intestine without being degraded, and delivers the component to the colon where the coating is digested by microbial fermentation and the component is released.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: December 27, 2016
    Inventor: Guy W. Miller
  • Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
    Patent number: 9526711
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: December 27, 2016
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Composition for inactivating an enveloped virus
    Patent number: 9526700
    Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: December 27, 2016
    Assignee: VIROBLOCK SA
    Inventors: Thierry Pelet, Donald F. H. Wallach
  • Pyrazine derivatives as ENaC blockers
    Patent number: 9522149
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: December 20, 2016
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Lee Edwards, Catherine Howsham, Peter Hunt, Nichola Smith
  • Tannin-containing gastrointestinal formulations and methods of use
    Patent number: 9522131
    Abstract: Tannin-containing compositions and methods of using same to enhance or maintain immune function during simplified nutrition feeding. Pharmaceutical compositions, including enteral nutrition compositions, are provided. The compositions comprise such tannins as proanthocyanidins and/or hydrolysable tannins. Administering the tannins to the gastrointestinal tract of a subject receiving simplified nutrition, such as with enteral nutrition therapy or parenteral nutrition therapy, attenuates or prevents deleterious effects on the gastrointestinal immune system that would otherwise occur with the simplified nutrition.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: December 20, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jess Dreher Reed, Dhanansayan Shanmuganayagam, Christian Gerald Krueger, Kenneth Allan Kudsk, Joseph Francis Pierre, Aaron F. Heneghan, Rodrigo P. Feliciano
  • Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
    Patent number: 9518044
    Abstract: The present invention is directed to compounds of Formula IC: wherein the substituents are described herein. These compounds and their pharmaceutically acceptable salts thereof are prostaglandin receptor EP2 antagonists.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: December 13, 2016
    Assignee: Emory University
    Inventors: Jianxiong Jiang, Thota Ganesh, Yuhong Du, Pahk Thepchatri, Yi Quan, Ray J. Dingledine
  • Method for the treatment of senile dementia of the Alzheimer's type
    Patent number: 9517222
    Abstract: The present invention relates to the treatment of Senile Dementia of the Alzheimer's Type (SDAT) by administering to the patient and effective amount of a compound selected from the group consisting of: 1-alkyl, 2-acyl-glyceraldehyde-3-phosphate (G3P); 1-alkyl, 2-acyl-glycerol; and 1-alkyl, 2-acyl-glycerylphosphatidylethanolamine (CGPE) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 13, 2016
    Assignee: Phenomenome Discoveries Inc.
    Inventor: Dayan Burke Goodenowe
  • Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation
    Patent number: 9512087
    Abstract: Disclosed herein are novel antifungal compounds of Formula 1, containing fluconazole pharmacophore moieties coupled with other moieties including aryl enones and chalcones and pharmaceutically acceptable salts thereof, methods for preparing these compounds and pharmaceutical preparations containing these novel compounds for prevention and treatment of fungal infections.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: December 6, 2016
    Assignee: Council for Scientific & Industrial Research
    Inventors: Hanumant Bapurao Borate, Sangmeshwer Prabhakar Sawargave, Subhash Prataprao Chavan, Mohan Anand Chandavarkar, Ramkrishnan Ramachaandran Iyer, Amit Chandrakant Tawte, Deepali Damodar Rao
  • Radiolabeled inhibitors of the amino acid transporters ASCT1 and ASCT2
    Patent number: 9512074
    Abstract: The present invention relates to a compound of Formula (I) or (II) or a salt thereof, wherein R is described herein. The compounds are novel hydroxy-proline analog inhibitors of the ASCT1 and ASCT2 neutral amino acid transporters.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: December 6, 2016
    Assignee: THE UNIVERSITY OF MONTANA
    Inventors: Christopher Sean Esslinger, Michael P. Kavanaugh, Brent Lyda, Nicholas R. Natale
  • Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
    Patent number: 9504693
    Abstract: This invention provides novel pharmaceutical compositions of the compound of formula (I): or a pharmaceutically acceptable salt thereof, that are suitable for the bulk production of an oral pharmaceutical dosage form; processes for the production of said oral pharmaceutical dosage form; and the use of the pharmaceutical composition for the treatment of patients suffering from or subject to diseases, disorders, or conditions involving cell survival, proliferation and migration, including chronic inflammatory proliferative disorders, proliferative ocular disorders, benign proliferative disorders, and cancer.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 29, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vijayalakshmi Ramanan, Irene S. Tobias, Raymond D. Skwierczynski, Dauntel S. Verwijs
  • Inhibition of dynamin related protein 1 to promote cell death
    Patent number: 9492450
    Abstract: The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp1 inhibition results in a disruption of the cell cycle and DNA aberrancies; (ii) inhibition of both Drp1 and ATR are synthetic lethal causing increased DNA damage and apoptotic cell death; and (iii) even in resistant cell lines, Drp1 inhibitor (e.g., mdivi-1) together with a second antiproliferative agent (e.g., cisplatin or carboplatin) act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: November 15, 2016
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Wei Qian, Bennett Van Houten
  • Use of pemirolast in the treatment of acute asthma
    Patent number: 9492454
    Abstract: According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: November 15, 2016
    Assignee: RSPR Pharma AB
    Inventors: Johan Raud, Carl-Johan Dalsgaard, Jesper Säfholm
  • Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases
    Patent number: 9486443
    Abstract: The present invention is a method for treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt and amlodipine or its pharmaceutically acceptable salt at a synergistic ratio of about 4:1.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: November 8, 2016
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Jong-Wook Lee, Sang-Ho Lee, Taek-Joo Lim, Eun-Ji Koh
  • Treatment of esophageal motility disorder using sepiapterin, tetrahydrobiopterin and derivatives thereof
    Patent number: 9486456
    Abstract: The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: November 8, 2016
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Pankaj J. Pasricha, Pandu R. R. Gangula